False negative results of QuantiFERON TB-2G test in patients with active tuberculosis. 2009

Yoshihiro Kobashi, and Hiroki Shimizu, and Yoshihiro Ohue, and Keiji Mouri, and Yasushi Obase, and Naoyuki Miyashita, and Mikio Oka
Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, Matsushima, Kurashiki, Japan. yoshihiro@med.kawasaki-m.ac.jp

Ten of 140 patients (7.1%) showed negative results on a QFT-2G test. The 10 patients consisted of seven males and three females (mean age: 66.0 years old). Three of the 10 patients had no clinical symptoms and no underlying diseases. They showed negative results on the QFT-2G test repeatedly within 1 month and a negative response on a tuberculin skin test (TST). Six of the seven remaining patients were of advanced age, and all of them had underlying diseases. Although all seven patients showed negative results on the QFT-2G test repeatedly within 1 month, one of them showed a negative response on TST. The lymphocyte count was within the normal range in three patients with nutritional conditions. Although five of nine patients with pulmonary tuberculosis had cavitary lesions, six had lesions within one-third of the unilateral lung field. The clinical effect in all patients was good. We suspect that there are two patterns by which false negative results are shown on QFT-2G tests; one pattern involves the decrease of interferon-gamma production due to advanced patient age or lymphocytopenia, and in the other lymphocytes cannot produce interferon-gamma for Mycobacterium tuberculosis-specific antigen in young patients without underlying disease.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D011933 Reagent Kits, Diagnostic Commercially prepared reagent sets, with accessory devices, containing all of the major components and literature necessary to perform one or more designated diagnostic tests or procedures. They may be for laboratory or personal use. Diagnostic Reagent Kits,Diagnostic Reagents and Test Kits,Diagnostic Test Kits,In Vitro Diagnostic Device,In Vitro Diagnostic Devices,In Vitro Diagnostic Medical Device,In Vitro Diagnostic Medical Devices,Kits, Diagnostic Reagent,Diagnostic Reagent Kit,Diagnostic Test Kit,Kit, Diagnostic Reagent,Kit, Diagnostic Test,Kits, Diagnostic Test,Reagent Kit, Diagnostic,Test Kit, Diagnostic,Test Kits, Diagnostic
D003951 Diagnostic Errors Incorrect or incomplete diagnoses following clinical or technical diagnostic procedures. Diagnostic Blind Spots,Errors, Diagnostic,Misdiagnosis,Blind Spot, Diagnostic,Blind Spots, Diagnostic,Diagnostic Blind Spot,Diagnostic Error,Error, Diagnostic,Misdiagnoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Yoshihiro Kobashi, and Hiroki Shimizu, and Yoshihiro Ohue, and Keiji Mouri, and Yasushi Obase, and Naoyuki Miyashita, and Mikio Oka
January 2012, Kekkaku : [Tuberculosis],
Yoshihiro Kobashi, and Hiroki Shimizu, and Yoshihiro Ohue, and Keiji Mouri, and Yasushi Obase, and Naoyuki Miyashita, and Mikio Oka
January 2009, Scandinavian journal of infectious diseases,
Yoshihiro Kobashi, and Hiroki Shimizu, and Yoshihiro Ohue, and Keiji Mouri, and Yasushi Obase, and Naoyuki Miyashita, and Mikio Oka
May 2008, Chest,
Yoshihiro Kobashi, and Hiroki Shimizu, and Yoshihiro Ohue, and Keiji Mouri, and Yasushi Obase, and Naoyuki Miyashita, and Mikio Oka
May 2012, Tuberculosis and respiratory diseases,
Yoshihiro Kobashi, and Hiroki Shimizu, and Yoshihiro Ohue, and Keiji Mouri, and Yasushi Obase, and Naoyuki Miyashita, and Mikio Oka
September 2018, BMC infectious diseases,
Yoshihiro Kobashi, and Hiroki Shimizu, and Yoshihiro Ohue, and Keiji Mouri, and Yasushi Obase, and Naoyuki Miyashita, and Mikio Oka
January 2008, Internal medicine (Tokyo, Japan),
Yoshihiro Kobashi, and Hiroki Shimizu, and Yoshihiro Ohue, and Keiji Mouri, and Yasushi Obase, and Naoyuki Miyashita, and Mikio Oka
June 2007, Kekkaku : [Tuberculosis],
Yoshihiro Kobashi, and Hiroki Shimizu, and Yoshihiro Ohue, and Keiji Mouri, and Yasushi Obase, and Naoyuki Miyashita, and Mikio Oka
August 2007, Kekkaku : [Tuberculosis],
Yoshihiro Kobashi, and Hiroki Shimizu, and Yoshihiro Ohue, and Keiji Mouri, and Yasushi Obase, and Naoyuki Miyashita, and Mikio Oka
November 2007, The European respiratory journal,
Yoshihiro Kobashi, and Hiroki Shimizu, and Yoshihiro Ohue, and Keiji Mouri, and Yasushi Obase, and Naoyuki Miyashita, and Mikio Oka
January 2007, Kekkaku : [Tuberculosis],
Copied contents to your clipboard!